{
  "name": "Amgen",
  "slug": "amgen",
  "ticker": "AMGN",
  "fetched_at": "2025-08-12T12:23:25.282598+00:00",
  "news": [
    {
      "title": "Amgen Announces Bemarituzumab’s Successful Phase 3 Results in FGFR2b+ Gastric Cancer - uk.finance.yahoo.com",
      "link": "https://news.google.com/rss/articles/CBMimwFBVV95cUxObHRiUlZKZzJ0UjF5cWowVlhUekhKYWlRY2ZGY3gxVXY4RHphNmo5WXN4VDc1d0JsdVRpazI4djNJNXpwWjVoelpPSEl4UXRFMWhicmtkVUlXaHhNbXRLTnd3YkRCVnZfLVhxbWR3dlFIanB2Q0EtYlF3RTBqeHFXVzlLQ0N4Y2NuYnFJWUswOEd6MDNXTjkyMVNPYw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimwFBVV95cUxObHRiUlZKZzJ0UjF5cWowVlhUekhKYWlRY2ZGY3gxVXY4RHphNmo5WXN4VDc1d0JsdVRpazI4djNJNXpwWjVoelpPSEl4UXRFMWhicmtkVUlXaHhNbXRLTnd3YkRCVnZfLVhxbWR3dlFIanB2Q0EtYlF3RTBqeHFXVzlLQ0N4Y2NuYnFJWUswOEd6MDNXTjkyMVNPYw?oc=5\" target=\"_blank\">Amgen Announces Bemarituzumab’s Successful Phase 3 Results in FGFR2b+ Gastric Cancer</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">uk.finance.yahoo.com</font>",
      "published": "2025-08-12T00:20:00+00:00",
      "source": "uk.finance.yahoo.com"
    },
    {
      "title": "Aveo Capital Partners LLC Lowers Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat",
      "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPQ19uT2tEMU5FWFBVUEVKUTE3ZkwzamlUZUt5Ym81NjhWOE9UUmFmSEIxZzgtSDY2eVRqak5FWGh0YVMyVEdyVnFHaE5SamJMcU5hd2FxWWtMUDlwbnpVLWNjamxrd2hqbURCSE5VcW5mNU1lTnNPU3pwd0kwTWZOZjU3T1RUVFdkamNual9LUFNSVzNMdEhLTHRyeWVNWEVZbTdqeUFOcEhrUng3UXJXLVptcC1xOGhHR0tUbWxPNlE?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPQ19uT2tEMU5FWFBVUEVKUTE3ZkwzamlUZUt5Ym81NjhWOE9UUmFmSEIxZzgtSDY2eVRqak5FWGh0YVMyVEdyVnFHaE5SamJMcU5hd2FxWWtMUDlwbnpVLWNjamxrd2hqbURCSE5VcW5mNU1lTnNPU3pwd0kwTWZOZjU3T1RUVFdkamNual9LUFNSVzNMdEhLTHRyeWVNWEVZbTdqeUFOcEhrUng3UXJXLVptcC1xOGhHR0tUbWxPNlE?oc=5\" target=\"_blank\">Aveo Capital Partners LLC Lowers Stake in Amgen Inc. (NASDAQ:AMGN)</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">MarketBeat</font>",
      "published": "2025-08-12T10:06:30+00:00",
      "source": "MarketBeat"
    },
    {
      "title": "S&P Pharma Giant Stumbles On Obesity Questions - Investor's Business Daily",
      "link": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNN29qeDRmUjg0MUxQd1lpMnlrcVZVY2ZhdVluVHZnTnhJaEE0YWQwSDUtMG5MSDRPVnFySUR4S0RBLXUzQzJSS2ZPMnh4Y3BRdDNBc21UWjBqU0lhanlLYXhrU1g0ci00Uk5mdWh4dkFBbFdIekdRTXh4RUF6RG1OYU5hSQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMigwFBVV95cUxNN29qeDRmUjg0MUxQd1lpMnlrcVZVY2ZhdVluVHZnTnhJaEE0YWQwSDUtMG5MSDRPVnFySUR4S0RBLXUzQzJSS2ZPMnh4Y3BRdDNBc21UWjBqU0lhanlLYXhrU1g0ci00Uk5mdWh4dkFBbFdIekdRTXh4RUF6RG1OYU5hSQ?oc=5\" target=\"_blank\">S&amp;P Pharma Giant Stumbles On Obesity Questions</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investor's Business Daily</font>",
      "published": "2025-08-06T20:23:00+00:00",
      "source": "Investor's Business Daily"
    },
    {
      "title": "AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS - PR Newswire",
      "link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSWhKMFgxZFhXQTJQWFZxN0FxTXNZQmUxcVNWcURLRGx2Y2VEazFUdEQwRTg3YVA4OWIzWlBxbXBrdlpaSjhBRmRKd0lHejlLS3Z5ZU5acVdMUmpHMnlJZS16c1NLWm9UMEdkeTQ1VFI3YUxXY1VmWGhDb2pWRmxOWFRYN3FaQjZFZkxnVjJsbWdCMU54UHk1R2lXQTRPc3pyNlk0VGtCSXFkT3M?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSWhKMFgxZFhXQTJQWFZxN0FxTXNZQmUxcVNWcURLRGx2Y2VEazFUdEQwRTg3YVA4OWIzWlBxbXBrdlpaSjhBRmRKd0lHejlLS3Z5ZU5acVdMUmpHMnlJZS16c1NLWm9UMEdkeTQ1VFI3YUxXY1VmWGhDb2pWRmxOWFRYN3FaQjZFZkxnVjJsbWdCMU54UHk1R2lXQTRPc3pyNlk0VGtCSXFkT3M?oc=5\" target=\"_blank\">AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">PR Newswire</font>",
      "published": "2025-08-05T20:01:00+00:00",
      "source": "PR Newswire"
    },
    {
      "title": "Amgen Welcomes Evolving Biosimilar Guidelines As Competitive Advantage - insights.citeline.com",
      "link": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxNUEVGc2lILTluMGZva3dVSWhBcjNUbW5tckhCemd4UVVEU21NVG1zYmRJM09sU1ZfTUpheUZ2RUlQazhWem5IR3dYdy1kWUQzb2x0YnU0UHAwZlIxT3BWc29zTmJta0E5cVdnaXBvOXRLTjZJNDVRWmR4bHlLZjdqQ1pPQXRoUXZWazZaT3ZvNjZWTFJua2lvdGVkTmpQRWE1dVA1ZHFBN18yczRDeHM4djBJNlZPZ1Z0WW9iMndhSFh2T2tKWEZuSXEwVlYxdWFTdllxS043SFhmeGhXMVV0LW90UXMySEsyM1l6aDc3VC1wUXVxQjJPT3N6TQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNUEVGc2lILTluMGZva3dVSWhBcjNUbW5tckhCemd4UVVEU21NVG1zYmRJM09sU1ZfTUpheUZ2RUlQazhWem5IR3dYdy1kWUQzb2x0YnU0UHAwZlIxT3BWc29zTmJta0E5cVdnaXBvOXRLTjZJNDVRWmR4bHlLZjdqQ1pPQXRoUXZWazZaT3ZvNjZWTFJua2lvdGVkTmpQRWE1dVA1ZHFBN18yczRDeHM4djBJNlZPZ1Z0WW9iMndhSFh2T2tKWEZuSXEwVlYxdWFTdllxS043SFhmeGhXMVV0LW90UXMySEsyM1l6aDc3VC1wUXVxQjJPT3N6TQ?oc=5\" target=\"_blank\">Amgen Welcomes Evolving Biosimilar Guidelines As Competitive Advantage</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">insights.citeline.com</font>",
      "published": "2025-08-11T13:56:21+00:00",
      "source": "insights.citeline.com"
    },
    {
      "title": "Earnings call transcript: Amgen beats Q2 2025 earnings expectations - Investing.com",
      "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxORlBWWm9GT18zeEVrblFqeW4wZmVjb2xkVFdzd3gtdEd5aFcyZ1BmRU1tRjlUS1YxYXFpOEtGTkxYSFkxSnBNREozaFNyOW1ROVFvRWhjeHJNemZmV3Rkd3BDWGJNYmtPM2JMN1VTa0NvcjFqdlkzQnROWDI1V18wdWhncERFQkwwM21TSXlwemhmNVRnOU9kTlhwVUh6TUJGemc4MjBkU18zcjg3Ykg1RVFuaWlMMVpiSElWb0pDVQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivwFBVV95cUxORlBWWm9GT18zeEVrblFqeW4wZmVjb2xkVFdzd3gtdEd5aFcyZ1BmRU1tRjlUS1YxYXFpOEtGTkxYSFkxSnBNREozaFNyOW1ROVFvRWhjeHJNemZmV3Rkd3BDWGJNYmtPM2JMN1VTa0NvcjFqdlkzQnROWDI1V18wdWhncERFQkwwM21TSXlwemhmNVRnOU9kTlhwVUh6TUJGemc4MjBkU18zcjg3Ykg1RVFuaWlMMVpiSElWb0pDVQ?oc=5\" target=\"_blank\">Earnings call transcript: Amgen beats Q2 2025 earnings expectations</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investing.com</font>",
      "published": "2025-08-05T22:20:56+00:00",
      "source": "Investing.com"
    },
    {
      "title": "How Amgen’s (AMGN) Strong Q2 Results and Buyback Pause Are Shaping Its 2025 Investment Story - simplywall.st",
      "link": "https://news.google.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?oc=5",
      "summary": "<a href=\"https://news.google.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?oc=5\" target=\"_blank\">How Amgen’s (AMGN) Strong Q2 Results and Buyback Pause Are Shaping Its 2025 Investment Story</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">simplywall.st</font>",
      "published": "2025-08-11T06:57:30+00:00",
      "source": "simplywall.st"
    },
    {
      "title": "Amgen’s Steady Profits Face Pressure From Patent Expirations - Finimize",
      "link": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE82V0E3N2g4Y1BQbTY1OXZrWVlncU9VSExudmZkSVlGMzNmd045dV9KNHJJY01Pc2pES0ozQkx3djE4ZEk4UzlsNFpzQnRQc2pjN2RUMmxieENNcmZT?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiXEFVX3lxTE82V0E3N2g4Y1BQbTY1OXZrWVlncU9VSExudmZkSVlGMzNmd045dV9KNHJJY01Pc2pES0ozQkx3djE4ZEk4UzlsNFpzQnRQc2pjN2RUMmxieENNcmZT?oc=5\" target=\"_blank\">Amgen’s Steady Profits Face Pressure From Patent Expirations</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Finimize</font>",
      "published": "2025-08-11T17:05:11+00:00",
      "source": "Finimize"
    }
  ],
  "product_launches": [
    {
      "title": "Boryung launches Samsung Bioepis' bone cancer biosimilar with storage edge over Amgen's Xgeva - koreabiomed.com",
      "link": "https://news.google.com/rss/articles/CBMibkFVX3lxTE51eEtJYkhkRHFlaDJiREhrQ3FTNFpINXVRT2xkNUo1dFROdWJLUF9fcm9EWVNWeW44S2JmR2FwQWpERUxRODRaTkZWRmpmQmFjWkQ5b0NaVm5DY005ZGlhTzQ4T2Z3ejJkT202am1R0gFyQVVfeXFMTWR6QWpUU2tQdnNiYmF2clROVVFIU2NFQzdnV3JOZUF0cHVaYVVmYTk0a01CSjA5N3ZMcnpZSllXWHhtWXZocnJySlgtMjhrbS1Yd1pIdEdOSzVVczllV0tFRHZRRjJ0dnJvbjZKOEdGandn?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMibkFVX3lxTE51eEtJYkhkRHFlaDJiREhrQ3FTNFpINXVRT2xkNUo1dFROdWJLUF9fcm9EWVNWeW44S2JmR2FwQWpERUxRODRaTkZWRmpmQmFjWkQ5b0NaVm5DY005ZGlhTzQ4T2Z3ejJkT202am1R0gFyQVVfeXFMTWR6QWpUU2tQdnNiYmF2clROVVFIU2NFQzdnV3JOZUF0cHVaYVVmYTk0a01CSjA5N3ZMcnpZSllXWHhtWXZocnJySlgtMjhrbS1Yd1pIdEdOSzVVczllV0tFRHZRRjJ0dnJvbjZKOEdGandn?oc=5\" target=\"_blank\">Boryung launches Samsung Bioepis' bone cancer biosimilar with storage edge over Amgen's Xgeva</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">koreabiomed.com</font>",
      "published": "2025-08-04T01:50:03+00:00",
      "source": "koreabiomed.com"
    },
    {
      "title": "Amgen settles Prolia patent suit with Celltrion, teeing up potential biosimilar launch in June - Fierce Pharma",
      "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxONkt3YUVEeUpwTU5LYVgtaTk2THhoMEt3ZUliWC1sWmhTTGR4M0hwaVpFMEFla01mUTdxbGVueWNGVThVT3U1T3R2NTQwaEkxeEI5MjRPMzVQUlhaU3hKNVVqQmFFY3BMQ2c3enphdTVLVy1Wb3dTb0l4Rnk3czFVTVFZbUdvVVJwa1I4Z3FDOFByVDZIV21Ccnk5VTd5U3VtNHhuVDdQUldHNm81YnZ6MHFReDBJNmk1S3BucTJhUlplcnc?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiwwFBVV95cUxONkt3YUVEeUpwTU5LYVgtaTk2THhoMEt3ZUliWC1sWmhTTGR4M0hwaVpFMEFla01mUTdxbGVueWNGVThVT3U1T3R2NTQwaEkxeEI5MjRPMzVQUlhaU3hKNVVqQmFFY3BMQ2c3enphdTVLVy1Wb3dTb0l4Rnk3czFVTVFZbUdvVVJwa1I4Z3FDOFByVDZIV21Ccnk5VTd5U3VtNHhuVDdQUldHNm81YnZ6MHFReDBJNmk1S3BucTJhUlplcnc?oc=5\" target=\"_blank\">Amgen settles Prolia patent suit with Celltrion, teeing up potential biosimilar launch in June</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Pharma</font>",
      "published": "2025-01-28T08:00:00+00:00",
      "source": "Fierce Pharma"
    },
    {
      "title": "Sandoz files antitrust suit in latest bid to launch biosimilar of Amgen's Enbrel in US - FirstWord Pharma",
      "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5VckVQdjB2RUpTc0p0YU1DYnpKMGJHbUt0b3djeEI1Sk91Mm9NLWJPQmpLUEhNYUtBZ1BUa21RVlQxcEhHdXpMa3dNMUs4NTd5dDhn?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5VckVQdjB2RUpTc0p0YU1DYnpKMGJHbUt0b3djeEI1Sk91Mm9NLWJPQmpLUEhNYUtBZ1BUa21RVlQxcEhHdXpMa3dNMUs4NTd5dDhn?oc=5\" target=\"_blank\">Sandoz files antitrust suit in latest bid to launch biosimilar of Amgen's Enbrel in US</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">FirstWord Pharma</font>",
      "published": "2025-04-14T07:00:00+00:00",
      "source": "FirstWord Pharma"
    },
    {
      "title": "Amgen Confirms Launch Of First US Eculizumab Rival - insights.citeline.com",
      "link": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQVHFOTU9KXzdESTJJc2dLZFF0Q1RMYTFoT3JHeElVd1pxUEdqbDRzdTZkZmQ3eWJZYmpGb1BLMTB6UVctcHVMLWUwNkluT280b215TDNBaFFranlMbll1S2w3QnlJWjFPNDVQZ3ZObmtfZlUxcXZJWEdIaU45Ym1heWJfWUpQTEtZRDNEY281UmprYkZab2RhS05HaUhRTjltZXZ6RG1SRnNlZzRHb05Yc2IwSWRlZHNKZzM1NWF5dzBxbTV2Zlo0blFBU291SkRSUU9QSl91dVJzRVFWakRHNA?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQVHFOTU9KXzdESTJJc2dLZFF0Q1RMYTFoT3JHeElVd1pxUEdqbDRzdTZkZmQ3eWJZYmpGb1BLMTB6UVctcHVMLWUwNkluT280b215TDNBaFFranlMbll1S2w3QnlJWjFPNDVQZ3ZObmtfZlUxcXZJWEdIaU45Ym1heWJfWUpQTEtZRDNEY281UmprYkZab2RhS05HaUhRTjltZXZ6RG1SRnNlZzRHb05Yc2IwSWRlZHNKZzM1NWF5dzBxbTV2Zlo0blFBU291SkRSUU9QSl91dVJzRVFWakRHNA?oc=5\" target=\"_blank\">Amgen Confirms Launch Of First US Eculizumab Rival</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">insights.citeline.com</font>",
      "published": "2025-03-05T08:00:00+00:00",
      "source": "insights.citeline.com"
    },
    {
      "title": "Strong first-quarter product sales for Amgen - The Pharma Letter",
      "link": "https://news.google.com/rss/articles/CBMiggFBVV95cUxObE5kVHJ3TmlvdEhBTmplQjgtVEVfdE1LQ1hmcmw2UThFaTg4aVk4eEtMbjdPR0dabHBaM0dMczZ5MlB2QWlxaDBCcXh3ZkRDWFVpbVRDMjQxbXdNS2JrYzFQYWd5ZWw3S0ZEcGdGRTRKRFE3eWszOFFkX1A0QWpfdkxB?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiggFBVV95cUxObE5kVHJ3TmlvdEhBTmplQjgtVEVfdE1LQ1hmcmw2UThFaTg4aVk4eEtMbjdPR0dabHBaM0dMczZ5MlB2QWlxaDBCcXh3ZkRDWFVpbVRDMjQxbXdNS2JrYzFQYWd5ZWw3S0ZEcGdGRTRKRFE3eWszOFFkX1A0QWpfdkxB?oc=5\" target=\"_blank\">Strong first-quarter product sales for Amgen</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Pharma Letter</font>",
      "published": "2025-05-02T07:00:00+00:00",
      "source": "The Pharma Letter"
    }
  ],
  "stock": {
    "ticker": "AMGN",
    "currency": "USD",
    "latest": {
      "date": "2025-08-11",
      "close": 285.0899963378906
    },
    "history": [
      {
        "date": "2025-08-01",
        "close": 296.8800048828125
      },
      {
        "date": "2025-08-04",
        "close": 301.94000244140625
      },
      {
        "date": "2025-08-05",
        "close": 300.0799865722656
      },
      {
        "date": "2025-08-06",
        "close": 284.6700134277344
      },
      {
        "date": "2025-08-07",
        "close": 284.70001220703125
      },
      {
        "date": "2025-08-08",
        "close": 288.2300109863281
      },
      {
        "date": "2025-08-11",
        "close": 285.0899963378906
      }
    ],
    "name": "Amgen Inc."
  }
}